CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 452 resultados LastUpdate Última actualización 05/02/2023 [11:29:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



previousPage Página2 de 19 nextPage   por página


SINGLE-DOMAIN ANTIBODY AND MODIFICATIONS THEREOF THAT SPECIFICALLY BIND TO THE RBD OF THE SARS-COV-2 S PROTEIN

NºPublicación: WO2023009028A1 02/02/2023

Solicitante:

FEDERAL STATE BUDGETARY INSTITUTION NATIONAL RES CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTE [RU]

RU_2763001_C1

Resumen de: WO2023009028A1

Claimed are a single-domain antibody that specifically binds to the RBD of the S protein of the SARS-CoV-2 virus and exhibits virus-neutralizing activity, an oligomerized single-domain antibody containing the aforementioned single-domain antibody as a monomeric unit, a single-domain antibody fused to an Fc fragment of human immunoglobulin G1, and an oligomerized single-domain antibody fused to an Fc fragment of human immunoglobulin G1. A method for the treatment or emergency prophylaxis of diseases caused by the SARS-CoV-2 virus consists in administering any of the aforementioned antibodies to a mammalian organism in an effective amount. In one embodiment, the single-domain antibody has an amino acid sequence selected from SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3. The invention is directed toward expanding the existing range of single-domain antibodies that are capable of effectively binding to the receptor-binding domain (RBD) of the SARS-CoV-2 S protein, neutralizing the SARS-CoV-2 virus and being used for the treatment or emergency prophylaxis of diseases caused by the SARS-CoV-2 virus.

traducir

MULTI-SUBUNIT SARS-COV-2 VACCINE

NºPublicación: WO2023008988A1 02/02/2023

Solicitante:

AUTONOMOUS ORGANIZATION OF EDUCATION NAZARBAYEV UNIV [KZ]

Resumen de: WO2023008988A1

Claimed is a vaccine that combines evolutionarily conserved B and T cell epitopes of human coronaviruses, inter alia SARS-CoV-2, to provide both humoral and cellular immunity. The high degree of sequence similarity between SARS-CoV-2 and other human coronaviruses (HCoVs) opens possibilities for the development of vaccines that will provide protection against SARS-CoV-2 and its current and future new variants, together with cross protection against other HCoVs. A bioinformatics analysis identifying T cell and B cell epitopes originating from spike, membrane, nucleocapsid or envelope protein sequences has shown that said epitopes are evolutionarily conserved among the seven main HCoVs. The evolutionary conservation of these epitopes indicates that they may play a crucial role in viral fitness and thus are unlikely to mutate during viral replication, which makes them attractive candidates for a vaccine. The proposed vaccine construct comprises 12 T cell and 6 B cell epitopes that are conserved among HCoVs.

traducir

COMPOSITION FOR PREVENTION OR TREATMENT OF CORONAVIRUS (SARS-COV-2) INFECTION, COMPRISING AGRIMONIA PILOSA EXTRACT AS ACTIVE INGREDIENT

NºPublicación: WO2023008594A1 02/02/2023

Solicitante:

APRG CO LTD [KR]

Resumen de: WO2023008594A1

The purpose of the present invention is to prepare a composition enabling prevention or treatment of coronavirus by using an Agrimonia pilosa extract, on the basis that a preventive, relieving or treatment effect of the Agrimonia pilosa extract on coronavirus infection has been confirmed.

traducir

Aerial Disinfection

NºPublicación: US2023034357A1 02/02/2023

Solicitante:

GRIGNARD PURE LLC [US]

Resumen de: US2023034357A1

This disclosure relates to a method for disinfecting a space. The method includes spraying a composition containing triethylene glycol into a space containing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an amount effective to inactivate SARS-CoV-2.

traducir

HAMED GMSH: GLUE MASK AND SHIELD FOR FACE

NºPublicación: WO2023007206A1 02/02/2023

Solicitante:

BAGHERI HAMED [IR]

Resumen de: WO2023007206A1

Using facial masks and shields are so important for those who work in conditions that should use masks and shields to protect themselves from diseases. To put an end to a respiratory ailment like covid-19 pandemic, ordinary people should wear masks or shie lds all day long, too. Thus, using masks and shields may arise different challenges for individuals. HAMED GMSH can help reducing the difficulties related to these circumstances and enhancing protective effects of masks and shields of any kinds, like general, surgical, respiratory, deodorant and so on. The idea of this invention is to use glues, liquids, solids or other sticky materials, for the purpose of holding masks and shields on humans' faces in replace of straps/bands or only nose wires. Key words: mask, shield, facial, face, surgical, deodorant, general, glue, stick, adhesive.

traducir

NEUTRALISING ANTIBODIES AND USES THEREOF

NºPublicación: WO2023004477A1 02/02/2023

Solicitante:

THE UNIV OF MELBOURNE [AU]

Resumen de: WO2023004477A1

The present invention relates to antibodies or antigen-binding fragments thereof that neutralise SARS-CoV-2, and uses thereof.

traducir

Compositions and methods for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-2), influenza A, and influenza B

NºPublicación: AU2021322710A1 02/02/2023

Solicitante:

F HOFFMANN LA ROCHE AG

US_2022042117_A1

Resumen de: AU2021322710A1

Methods for the rapid detection of the presence or absence of SARS-CoV-2 in biological or non-biological samples are described. These methods are adapted to be performed rapidly in a point-of-care setting. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Specifically, primers and probes targeting the orf1ab gene or the N gene of SARS-CoV-2 are provided that are designed for the detection of this target. Additionally, kits and reaction vessels containing primers and probes targeting SARS-CoV-2 are provided. Additionally, methods, kits and reaction vessels for the simultaneous rapid detection of the presence or absence of SARS-CoV-2, influenza A, and influenza B in biological or non-biological samples are described.

traducir

COVID-19 mucosal antibody assay

NºPublicación: AU2021312381A1 02/02/2023

Solicitante:

NANTCELL INC

WO_2022018528_A1

Resumen de: AU2021312381A1

Methods and compositions are disclosed for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (

traducir

Systems and methods for rapid inactivation of SARS-CoV-2 by silicon nitride and aluminum nitride

NºPublicación: AU2021301031A1 02/02/2023

Solicitante:

SINTX TECHNOLOGIES INC

BR_112022026025_PA

Resumen de: AU2021301031A1

Various embodiments related to systems, methods, and articles for rapid inactivation of SARS-CoV-2 by silicon nitride and aluminum nitride are disclosed herein.

traducir

Protective mask

NºPublicación: AU2021300284A1 02/02/2023

Solicitante:

INTELLISAFE LLC

US_2022304404_PA

Resumen de: AU2021300284A1

The present disclosure relates to a protective mask to deactivate damaging agents. In some examples, the mask includes a filter element that traps particles of the damaging agent. A sanitizing emitter permeates the filter element with a sanitizing agent to deactivate the damaging agent. In some examples, the sanitizing agent is ultraviolet light configured to deactivate a virus such as SARS-CoV-2.

traducir

Binding proteins recognizing SARS-CoV-2 antigens and uses thereof

NºPublicación: AU2021311470A1 02/02/2023

Solicitante:

TSCAN THERAPEUTICS INC
AHS HOSPITAL CORP

Anti-protein S single-domain antibodies and polypeptides comprising thereof

NºPublicación: AU2021299932A1 02/02/2023

Solicitante:

INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE
ASSIST PUBLIQUE HOPITAUX DE PARIS APHP
UNIV PARIS SACLAY

WO_2022002880_A1

Resumen de: AU2021299932A1

Vitamin K-dependent Protein S (PS) is a natural anticoagulant acting as a non-enzymatic cofactor for both activated protein C (APC) and tissue factor pathway inhibitor (TFPI). The inventors identify an anti-PS nanobody that very surprisingly enhances the APC- cofactor activity of PS through unknown mechanisms. Very interestingly, this nanobody exerts an antithrombotic effect in injured mesenteric microvessels of mice. As a consequence, it10 constitutes a novel class of antithrombotic agents that could be used for the treatment of acute microthrombosis in pathological states such as sepsis, COVID-19, distal microvascular thrombosis induced by stroke, or sickle-cell disease. Thus, the present invention relates to isolated single-domain antibodies (sdAb) directed against protein S (PS) and polypeptides comprising thereof.

traducir

Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

NºPublicación: AU2021297245A1 02/02/2023

Solicitante:

THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE
ILLUMINA SOFTWARE INC

WO_2021262894_A1

Resumen de: AU2021297245A1

Provided by the inventive concept is a DNA methylation-based platform, and machine learning algorithms, for diagnosing respiratory pathogens including SARS-CoV-2 and predicting COVID-19 related outcomes, and methods of using the same, such as in identifying the presence of a viral infection, such as a SARS-CoV-2 infection, determining whether a subject has COVID-19, and/or whether a subject with COVID-19 is likely to develop acute respiratory distress syndrome or multisystem inflammatory syndrome in children.

traducir

Anti-CCR5 monoclonal antibody-based compositions and methods

NºPublicación: AU2021297217A1 02/02/2023

Solicitante:

MADDON ADVISORS LLC

WO_2021262632_A2

Resumen de: AU2021297217A1

This invention provides humanized IgG4 monoclonal antibodies having the light and heavy chain variable region amino acid sequences of PRO 140, wherein the antibody comprises (i) a heavy chain modification that inhibits half antibody formation, (ii) a heavy chain modification that increases the antibody's terminal half-life, and, optionally, (iii) a heavy chain modification that lowers the antibody's effector function. This invention also provides a related humanized IgG2/IgG4 monoclonal fusion antibody. This invention further provides related nucleic acid molecules; recombinant vectors; recombinant AAV particles; pharmaceutical compositions; prophylactic and therapeutic methods for addressing HIV-1 infection, SARS-CoV-2 infection, and CCR5-mediated disorders; and kits for performing these methods.

traducir

Methods of detecting SARS-CoV-2, influenza, and RSV

NºPublicación: AU2021294330A1 02/02/2023

Solicitante:

CEPHEID

Resumen de: AU2021294330A1

Compositions and methods for detecting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), influenza A, influenza B, and respiratory syncytial virus (RSV) are provided.

traducir

Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (uPAR) for treatment of severe COVID-19 disease

NºPublicación: AU2021292488A1 02/02/2023

Solicitante:

MONOPAR THERAPEUTICS INC

WO_2021257552_A1

Resumen de: AU2021292488A1

Antibodies specific for uPAR and uPA-uPAR complexes in the form of radioconjugates with alpha particle—emitting radionuclides are disclosed as is their use in treating severe respiratory diseases such as severe COVID-19.

traducir

Saliva-based molecular testing for SARS-CoV-2

NºPublicación: AU2021292309A1 02/02/2023

Solicitante:

THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

US_2022275464_A1

Resumen de: AU2021292309A1

A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.

traducir

Hyperimmune IgG and/or IgM compositions and method for preparing thereof and method for obtaining hyperimmune human plasma from a donor

NºPublicación: AU2021284903A1 02/02/2023

Solicitante:

GRIFOLS WORLDWIDE OPERATIONS LTD

Resumen de: AU2021284903A1

The present disclosure refers to a liquid therapeutic hyperimmune globulin composition comprising human plasma-derived immunoglobulin G (IgG) having antibody titre between 250 and 2,500 per mg/mL of IgG and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titer) between 1.5 and 15 per mg/mL of IgG for use in the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof. It also refers to a liquid therapeutic or prophylactic hyperimmune immunoglobulin composition comprising human plasma-derived immunoglobulin M (IgM) having a SARS-CoV-2 titre between 2,000 and 17,000 and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titre) between 200 and 70,000, methods for preparing thereof, and the use thereof for the treatment or prophylaxis of COVID-19. Finally, it also refers to a method for obtaining hyperimmune human plasma from a donor for use in the treatment of COVID-19.

traducir

Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

NºPublicación: AU2021283349A1 02/02/2023

Solicitante:

REGENERON PHARMACEUTICALS INC

US_2021395345_A1

Resumen de: AU2021283349A1

The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (

traducir

Systems and processes to screen for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) of 2019 (COVID-19)

NºPublicación: AU2021283210A1 02/02/2023

Solicitante:

BATTELLE MEMORIAL INST

AU_2021283288_A1

Resumen de: AU2021283210A1

Systems and processes to screen for SARS-CoV-2, which includes a process that uses an alternative antibody for ELISA. The alternative antibody is an alternative to a mouse antibody, thereby expanding the ability to test for COVID-19 using non-human antibodies.

traducir

Compositions and methods for treating acute respiratory distress syndrome (ARDS) and inflammatory disorders caused by coronaviruses

NºPublicación: AU2021281257A1 02/02/2023

Solicitante:

PHOR MED INC [US]

Resumen de: AU2021281257A1

Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-CoV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-CoV-2/COVID-l 9 cases.

traducir

A composition for management of COVID-19 and associated disorders

NºPublicación: AU2021281159A1 02/02/2023

Solicitante:

VEDICINALS INDIA PRIVATE LTD

WO_2021240481_A2

Resumen de: AU2021281159A1

The present disclosure provides a composition that may find utility in management of COVID-19. The inventors of the present disclosure surprisingly observed that ingredients of the composition of the present disclosure exhibit functional synergy therebetween, wherein the composition prevents virus replication and/or Virus entry into human cells, either wholly or in part, while modulating immune response of the patient. Hence, the composition of the present disclosure holds potential for wide spread usage in management of COVID-19, either alone or in combination with other preventive or palliative/symptomatic or therapeutic strategies.

traducir

Methods of generating vaccines against novel coronavirus, named SARS-CoV-2 comprising variable epitope libraries (VELS) as immunogens

NºPublicación: AU2021265260A1 02/02/2023

Solicitante:

PRIMEX CLINICAL LABORATORIES INC

WO_2021222717_A2

Resumen de: AU2021265260A1

Described herein is the application of Variable Epitope Libraries (VELs) as immunogens for the generation of vaccines against a novel coronavirus, named SARS-CoV-2. The VELs bearing combinatorial epitope libraries target antigenic variability of viruses such as SARS-CoV-2, and cancer, thus representing a true alternative to traditional vaccine platforms.

traducir

Optimized nucleotide sequences encoding SARS-CoV-2 antigens

NºPublicación: AU2021269042A1 02/02/2023

Solicitante:

TRANSLATE BIO INC

WO_2021226436_PA

Resumen de: AU2021269042A1

The present invention relates to optimized nucleotide sequence encoding SARS-CoV-2 antigens. These sequences are particularly suitable for use in vaccine compositions for the treatment or prevention of infections caused by a β-coronaviruses, including COVID-19 infections, in a human or animal subject in need of such treatment.

traducir

SARS-CoV-2 vaccines

Nº publicación: AU2021272741A1 02/02/2023

Solicitante:

JANSSEN PHARMACEUTICALS INC

BR_112022022859_PA

Resumen de: AU2021272741A1

RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons.

traducir

previousPage Página2 de 19 nextPage por página

punteroimgVolver